Trial Profile
A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed therapy with corticosteroids
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms AZTEC
- 04 May 2022 Status changed to completed.
- 26 Aug 2021 Status changed from active, no longer recruiting to discontinued, as per results published in the Bone Marrow Transplantation.
- 26 Aug 2021 Primary endpoint (Best overall response) has been met, as per results published in the Bone Marrow Transplantation.